Cargando…

TP53 mutations among molecular subtypes of HER2-positive tumors

Detalles Bibliográficos
Autores principales:	Helland, Å, Nicolau, M, Ji, Y, Langerød, A, Sommervoll, DE, Bergamaschi, A, Pollack, JR, Børresen-Dale, A-L, Jeffrey, SS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233596/ http://dx.doi.org/10.1186/bcr1175

Ejemplares similares

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection
por: Due, EU, et al.
Publicado: (2005)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
por: Olivier, M, et al.
Publicado: (2005)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
por: Helland, A., et al.
Publicado: (1998)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
por: Holstege, Henne, et al.
Publicado: (2010)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
por: Baumbusch, Lars O, et al.
Publicado: (2006)

Characterization of extracellular matrix composition in breast carcinoma
por: Bergamaschi, A, et al.
Publicado: (2005)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

Discovery and validation of breast cancer subtypes
por: Kapp, Amy V, et al.
Publicado: (2007)

Discovery and validation of breast cancer subtypes
por: Kapp, Amy V, et al.
Publicado: (2006)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Mutant p53 exerts its gain of function through activation of the NF-κB pathway
por: Damalas, A, et al.
Publicado: (2005)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
por: Husby, S., et al.
Publicado: (2022)

Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
por: Clarke, Stephen L., et al.
Publicado: (2019)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Immortalization-associated gene signature in breast cancer
por: Dairkee, SH, et al.
Publicado: (2005)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Gene expression studies in radiation-sensitive cell lines
por: Aarøe, J, et al.
Publicado: (2005)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

TP53 Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes
por: Coradini, Danila, et al.
Publicado: (2012)

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Thota, Ramya, et al.
Publicado: (2021)

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
por: Ragu, Mohana Eswari, et al.
Publicado: (2023)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Application of microarray analyses to identify genes involved in radiation-induced fibrosis
por: Rødningen, OK, et al.
Publicado: (2005)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

Lessons from TP53 mutations in breast cancers: from carcinogen fingerprints to clinical correlates
por: Hainaut, P, et al.
Publicado: (2000)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Cell death induced by HDACS inhibitors in ovarian cancer cell lines (serous and clear cells carcinomas) – role of NOTCH, TP53 and FN1
por: Silva, Fernanda, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l5iakiu4ae58sm1s0el36l99bf